Michael Porter's Five Forces model is a framework to study the global anti-obesity drugs market. Strategic business managers trying to gain an edge over competing firms in the global anti-obesity drugs market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the Global anti-obesity drugs market have been broken down and analyzed.
PORTER'S FIVE FORCES ANALYSIs: Global anti-obesity drugs market
Threat of New Entrants
The threat of new entrants in the global anti-obesity drugs market is moderate to high. While the market offers significant growth opportunities due to rising obesity rates and an aging population, entering this industry requires substantial investment in research and development (R&D), clinical trials, and regulatory approvals, which can be barriers for new companies. However, the lucrative nature of the market, driven by increasing consumer demand and the need for innovative treatments, might attract new players. Additionally, smaller biotech firms and startups could introduce novel products or solutions, increasing competition. Established brands can also acquire new entrants, lowering the risk for them.
BARGAINING POWER OF SUPPLIERS
The bargaining power of suppliers in the anti-obesity drugs market is relatively low to moderate. The ingredients and raw materials used in the production of these drugs are sourced from multiple suppliers globally, which reduces the dependency on any single supplier. However, the complexity of pharmaceutical production and the need for high-quality ingredients, especially for active pharmaceutical ingredients (APIs), may grant some suppliers a degree of bargaining power, especially in cases where proprietary or specialized compounds are involved. Additionally, patent protections for certain formulations could give suppliers a more influential role.
Threat of Substitutes
The threat of substitutes in the anti-obesity drugs market is moderate. There are various non-pharmaceutical alternatives available, such as dietary changes, exercise programs, and bariatric surgery, which can serve as substitutes for anti-obesity drugs. While these alternatives can be effective for some individuals, many people seek the convenience and effectiveness that drugs offer, especially for long-term weight management. However, increasing awareness of the risks of long-term drug use and side effects might encourage consumers to opt for lifestyle interventions or natural supplements, impacting demand for pharmaceutical solutions.
Bargaining Power of Buyers
The bargaining power of buyers in the anti-obesity drugs market is high due to the growing number of treatment options available, giving consumers the ability to choose between various drugs based on price, effectiveness, and side effects. Additionally, healthcare providers, insurers, and government entities play a significant role in shaping the market by determining reimbursement policies and the availability of certain drugs. If a drug fails to show strong results or has adverse side effects, buyers can easily switch to alternatives. This, combined with growing public awareness of treatment options, shifts bargaining power toward buyers.
Intensity of Rivalry
The intensity of rivalry in the global anti-obesity drugs market is high, driven by numerous large pharmaceutical companies and emerging biotech firms competing for market share. Well-established players, such as Novo Nordisk, Eli Lilly, and others, have strong brands and extensive resources, making it challenging for new entrants to gain significant traction. However, the market is also characterized by innovation, with ongoing R&D efforts to create more effective and safer medications. The increasing prevalence of obesity, combined with rising demand for anti-obesity treatments, intensifies the competition, as companies strive to differentiate their products and capture consumer attention in a growing and dynamic market.
IMPACT OF COVID-19 on GLOBAL ANTI-OBESITY DRUGS MARKET
The COVID-19 pandemic had a complex and multifaceted impact on the global anti-obesity drugs market, with both challenges and opportunities emerging. On the negative side, the pandemic disrupted global supply chains, causing delays in the production and distribution of pharmaceutical products, including anti-obesity medications. With lockdowns and restrictions in place, pharmaceutical manufacturers struggled to maintain normal production levels, leading to shortages and delays in the availability of drugs. The strain on healthcare systems, particularly in the early stages of the pandemic, resulted in many non-essential medical appointments being postponed, including those for weight management. This meant fewer patients sought advice or prescriptions for anti-obesity medications, which led to a short-term decline in demand. Additionally, the economic downturn caused by the pandemic resulted in financial uncertainty for many consumers, impacting their ability to afford weight management treatments, particularly in regions where these drugs are not covered by insurance.
However, the pandemic also had a positive effect on the anti-obesity drugs market in the long term. As COVID-19 highlighted the increased vulnerability of individuals with obesity to severe illness and death, public awareness of the health risks associated with obesity grew. Many individuals, especially those in higher-risk categories, began to focus more on improving their health by managing their weight. This shift in mindset led to an increased demand for weight management solutions, including anti-obesity medications, as people sought to mitigate the risks associated with obesity and improve their overall well-being. Furthermore, the widespread adoption of telemedicine during the pandemic allowed healthcare providers to continue offering consultations for weight management remotely. This transition helped individuals access weight management treatments without the need for in-person visits, broadening the market's reach and increasing demand for anti-obesity drugs.
In summary, while the COVID-19 pandemic posed challenges to the global anti-obesity drugs market, such as supply chain disruptions and reduced access to healthcare, it also created new opportunities. The heightened awareness of obesity-related health risks and the growth of telemedicine are likely to drive sustained demand for anti-obesity medications. As a result, the long-term outlook for the market remains positive, with increasing consumer focus on health and wellness, as well as a growing need for effective obesity treatments in a post-pandemic world.
Market Trends
The anti-obesity drug market is undergoing significant transformations, driven by several key trends that reflect both evolving consumer needs and the advancement of scientific research. These trends have reshaped the landscape and are fueling future growth. Below are some of the most notable market trends currently shaping the industry:
Emerging Competitors: The global anti-obesity drugs market is experiencing heightened competition as new players enter the field. These emerging competitors, including both established pharmaceutical giants and innovative startups, are developing novel therapies to address obesity, a condition that remains a global health challenge. For instance, in November 2024, Amgen announced promising results from its Phase 2 study of MariTide (maridebart cafraglutide), an investigational obesity treatment. At 52 weeks, MariTide demonstrated up to 20% average weight loss in people with obesity or overweight, without a weight loss plateau, suggesting continued potential for weight loss beyond the study period. In those with Type 2 diabetes, MariTide achieved up to 17% average weight loss and reduced HbA1c by up to 2.2 percentage points.
